Description générale
Cytarabine is a pyrimidine nucleoside analogue antineoplastic agent used in the treatment of leukaemias and lymphomas.
INN
Cytarabine
Codes ATC
Type de médicament
Chemical agent
Historique des statuts LME
Ajouté pour la première fois en 1979
(TRS
641)
pour
Lymphoid leukaemia, not elsewhere classified
Ajouté en 1979
(TRS
641)
pour
Myeloid leukaemia
Ajouté en 1979
(TRS
641)
pour
Acute myeloid leukaemia with recurrent genetic abnormalities
Ajouté en 1979
(TRS
641)
pour
Burkitt lymphoma including Burkitt leukaemia
Ajouté en 1979
(TRS
641)
pour
Unspecified malignant neoplasms of unspecified sites
Retiré en 2015
(TRS
994)
pour
Unspecified malignant neoplasms of unspecified sites
Ajouté en 2023
(TRS
1049)
pour
Anaplastic large cell lymphoma, ALK-positive
Ajouté en 2023
(TRS
1049)
pour
Anaplastic large cell lymphoma, ALK-negative
Ajouté en 2023
(TRS
1049)
pour
Langerhans cell histiocytosis
Wikipédia
DrugBank
Recommandations
Section
Cytotoxic medicines
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Indications
Lymphoid leukaemia, not elsewhere classified
Myeloid leukaemia
Acute myeloid leukaemia with recurrent genetic abnormalities
Burkitt lymphoma including Burkitt leukaemia
Unspecified malignant neoplasms of unspecified sites
Anaplastic large cell lymphoma, ALK-positive
Anaplastic large cell lymphoma, ALK-negative
Langerhans cell histiocytosis